PetMed Express Q2 FY2025: net sales $59.6M, net income $2.3M, EPS $0.11

PETMED EXPRESS INC

2025-Q2 EPS reported $0.29 vs consensus -$0.07 ▲ beat (+506.2%)

Net sales of $59.6M; net income $2.3M ($0.11 diluted EPS) vs $0.7M ($0.03) in prior year.
Gross margin 29.1% (+0.8% YoY); Adjusted EBITDA $2.1M, sequential improvement from $(1.5)M in Q1.
CEO cites cost savings from consolidating PetMeds/PetCareRx ops; positioned for growth initiatives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.